Excedrin Extra Strength OTC indication for migraine pain supported by studies -- Bristol.
This article was originally published in The Tan Sheet
Executive Summary
EXCEDRIN EXTRA STRENGTH OTC INDICATION FOR MIGRAINE PAIN is supported by three clinical trials involving subjects with migraine, according to Bristol-Myers Squibb. Results of the trials, which include comparisons of Excedrin Extra Strength to placebo and to prescription migraine drugs, will be presented by the company at the July 15 joint meeting of FDA's Nonprescription Drugs and Arthritis Advisory Committees ("The Tan Sheet" June 2, p. 3). Representatives from the agency's Peripheral & Central Nervous System Advisory Committee also will attend.